Importantly, treatment with anti-CD44 antibody improved insulin resistance, adipose inflammation, hepatic steatosis and weight gain in diet induced obese mice (Kodama et al., 2015), reflecting the potential impact of modulating T cell receptors on the outcome of metabolic diseases. This evidence concerns the gene CD44 and fatty liver disease.